Vor Biopharma Inc. (VOR)

Vor Biopharma Statistics

Total Valuation

Vor Biopharma has a market cap or net worth of $514.85 million. The enterprise value is $347.44 million.

Market Cap	514.85M
Enterprise Value	347.44M

Important Dates

The next estimated earnings date is Thursday, March 19, 2026, after market close.

Earnings Date	Mar 19, 2026
Ex-Dividend Date	n/a

Share Statistics

Vor Biopharma has 41.52 million shares outstanding. The number of shares has increased by 66.44% in one year.

Current Share Class	41.52M
Shares Outstanding	41.52M
Shares Change (YoY)	+66.44%
Shares Change (QoQ)	+6.68%
Owned by Insiders (%)	2.86%
Owned by Institutions (%)	13.90%
Float	25.96M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	n/a
Forward PS	n/a
PB Ratio	n/a
P/TBV Ratio	n/a
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Enterprise Valuation

EV / Earnings	n/a
EV / Sales	n/a
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 9.16

Current Ratio	9.16
Quick Ratio	9.05
Debt / Equity	n/a
Debt / EBITDA	n/a
Debt / FCF	n/a
Interest Coverage	n/a

Financial Efficiency

Return on Equity (ROE)	n/a
Return on Assets (ROA)	-144.27%
Return on Invested Capital (ROIC)	n/a
Return on Capital Employed (ROCE)	-214.29%
Weighted Average Cost of Capital (WACC)	15.30%
Revenue Per Employee	n/a
Profits Per Employee	-$15.91M
Employee Count	154
Asset Turnover	n/a
Inventory Turnover	n/a

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -53.73% in the last 52 weeks. The beta is 2.03, so Vor Biopharma's price volatility has been higher than the market average.

Beta (5Y)	2.03
52-Week Price Change	-53.73%
50-Day Moving Average	12.46
200-Day Moving Average	22.38
Relative Strength Index (RSI)	42.39
Average Volume (20 Days)	980,496

Short Selling Information

The latest short interest is 2.19 million, so 5.27% of the outstanding shares have been sold short.

Short Interest	2.19M
Short Previous Month	2.27M
Short % of Shares Out	5.27%
Short % of Float	8.43%
Short Ratio (days to cover)	1.60

Income Statement

Revenue	n/a
Gross Profit	n/a
Operating Income	-337.29M
Pretax Income	-2.45B
Net Income	-2.45B
EBITDA	-333.56M
EBIT	-337.29M
Earnings Per Share (EPS)	-$431.80

Balance Sheet

The company has $170.46 million in cash and $3.06 million in debt, with a net cash position of $167.40 million or $4.03 per share.

Cash & Cash Equivalents	170.46M
Total Debt	3.06M
Net Cash	167.40M
Net Cash Per Share	$4.03
Equity (Book Value)	-2.23B
Book Value Per Share	-246.54
Working Capital	153.65M

Cash Flow

In the last 12 months, operating cash flow was -$143.98 million and capital expenditures -$699,000, giving a free cash flow of -$144.67 million.

Operating Cash Flow	-143.98M
Capital Expenditures	-699,000
Free Cash Flow	-144.67M
FCF Per Share	-$3.48

Margins

Gross Margin	n/a
Operating Margin	n/a
Pretax Margin	n/a
Profit Margin	n/a
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	n/a

Dividends & Yields

Vor Biopharma does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-66.44%
Shareholder Yield	-66.44%
Earnings Yield	-475.78%
FCF Yield	-28.10%

Analyst Forecast

The average price target for Vor Biopharma is $64.78, which is 422.42% higher than the current price. The consensus rating is "Buy".

Price Target	$64.78
Price Target Difference	422.42%
Analyst Consensus	Buy
Analyst Count	10
Revenue Growth Forecast (5Y)	n/a
EPS Growth Forecast (5Y)	n/a

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

The last stock split was on September 19, 2025. It was a reverse split with a ratio of 1:20.

Last Split Date	Sep 19, 2025
Split Type	Reverse
Split Ratio	1:20

Scores

Altman Z-Score	n/a
Piotroski F-Score	2